Tuoxin Pharmaceutical Group Co.,Ltd. (301089.SZ) announced that its wholly-owned subsidiary, Xinxiang Pharmaceutical Co., Ltd., recently received two "Drug GMP Compliance Inspection Letters" issued by the Henan Provincial Medical Products Administration.
The inspection confirms that Xinxiang Pharmaceutical's relevant workshops and production lines for the active pharmaceutical ingredients Olaparib (an anti-tumor drug) and Citicoline have passed the Good Manufacturing Practice compliance check, signifying that the company's corresponding production facilities and management system meet the requirements for pharmaceutical quality management.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.